Venn Life Sciences wins new contracts

Venn Life Sciences has won two contracts to provide a number of clinical trial-management services across Europe.

Venn Life Sciences has won two contracts to provide a number of clinical trial-management services across Europe.

The first contract is with a global pharmaceutical company to conduct a Phase IV drug interaction study and the second is with a leading US biotech company to manage a multi-national study. The group said it could not name either of the companies due to confidentiality agreements.

The new deals, combined with other recent contract wins, will contribute €0.9m in additional revenue for the financial year to December 31st 2013.

Venn also announced it has opened a new office in the UK and has appointed Stewart Hulse as Vice President of Resourcing.

"These recent business wins and the expansion of our business are in line with our goals as set out earlier this year," Chief Executive Officer, Tony Richardson, said.

"We have targeted medical devices as a key growth area and the recent project win is a welcome endorsement of our capabilities. Securing preferred vendor status with top ten Pharma is a major achievement for a company of our current scale and reflects well on the robustness of our business."

RD

Recommended

How to be better at selling stocks
Investment strategy

How to be better at selling stocks

There is plenty of advice around about buying stocks, but not so much about when you should sell. John Stepek explains the two key things to know abou…
14 Jan 2022
Share tips of the week – 14 January
Share tips

Share tips of the week – 14 January

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
14 Jan 2022
Fintech: how to profit as technology transforms banking around the world
Share tips

Fintech: how to profit as technology transforms banking around the world

Financial technology – from apps to APIs to the cloud – is rapidly transforming financial services. This will spell doom for some incumbent firms, whi…
14 Jan 2022
Three solid assets to buy for a low interest-rate world
Share tips

Three solid assets to buy for a low interest-rate world

Professional investor Luke Hyde-Smith of the Waverton Real Assets Fund, highlights three alternative investments to diversify your portfolio.
14 Jan 2022

Most Popular

Five unexpected events that could shock the markets in 2022
Stockmarkets

Five unexpected events that could shock the markets in 2022

Forget Covid-19 – it’s the unexpected twists that will rattle markets in 2022, says Matthew Lynn. Here are five possibilities
31 Dec 2021
Which investment trusts performed the best in 2021?
Investment trusts

Which investment trusts performed the best in 2021?

Shivani Khandekar runs through the top ten investment trusts of 2021 – and the worst performing trusts – and looks ahead to 2022.
7 Jan 2022
Interest rates might rise faster than expected – what does that mean for your money?
Global Economy

Interest rates might rise faster than expected – what does that mean for your money?

The idea that the US Federal Reserve could raise interest rates much earlier than anticipated has upset the markets. John Stepek explains why, and wha…
6 Jan 2022